MA29323B1 - Composes de l'acide pyridylacetique - Google Patents

Composes de l'acide pyridylacetique

Info

Publication number
MA29323B1
MA29323B1 MA30205A MA30205A MA29323B1 MA 29323 B1 MA29323 B1 MA 29323B1 MA 30205 A MA30205 A MA 30205A MA 30205 A MA30205 A MA 30205A MA 29323 B1 MA29323 B1 MA 29323B1
Authority
MA
Morocco
Prior art keywords
optionally substituted
group
alkyl group
atom
compounds
Prior art date
Application number
MA30205A
Other languages
English (en)
Inventor
Hironobu Maezaki
Nobuhiro Suzuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36370977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29323(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA29323B1 publication Critical patent/MA29323B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (I) : DANS LAQUELLE R1 EST UN GROUPE ALKYLE EN C1-6 FACULTATIVEMENT SUBSTITUÉ PAR UN GROUPE CYCLOALKYLE EN C3-10, R2 EST UN GROUPE ALKYLE EN C2-6, R3 EST UN ATOME D'HYDROGÈNE, UN GROUPE ALKYLE EN C1-6 OU UN ATOME D'HALOGÈNE ET X EST -OR6 OU -NR4R5 OÙ R4 ET R6 SONT CHACUN INDÉPENDAMMENT UN ATOME D'HYDROGÈNE, UN GROUPE HYDROCARBONÉ FACULTATIVEMENT SUBSTITUÉ OU UN GROUPE HÉTÉROCYCLIQUE FACULTATIVEMENT SUBSTITUÉ, R5 EST UN GROUPE HYDROCARBONÉ FACULTATIVEMENT SUBSTITUÉ, UN GROUPE HÉTÉROCYCLIQUE FACULTATIVEMENT SUBSTITUÉ OU UN GROUPE HYDROXYLÉ FACULTATIVEMENT SUBSTITUÉ OU BIEN R4 ET R5 FORMENT FACULTATIVEMENT AVEC L'ATOME D'AZOTE ADJACENT UN HÉTÉROCYCLE CONTENANT DE L'AZOTE FACULTATIVEMENT SUBSTITUÉ, OU UN SEL DE CELUI-CI. LE COMPOSÉ DE LA PRÉSENTE INVENTION PRÉSENTE UN EFFET SUPÉRIEUR D'INHIBITION DE PEPTIDASES ET IL EST UTILE COMME AGENT POUR LA PROPHYLAXIE OU LE TRAITEMENT DU DIABÈTE ET SIMILAIRE.
MA30205A 2005-02-25 2007-09-10 Composes de l'acide pyridylacetique MA29323B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005052018 2005-02-25

Publications (1)

Publication Number Publication Date
MA29323B1 true MA29323B1 (fr) 2008-03-03

Family

ID=36370977

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30205A MA29323B1 (fr) 2005-02-25 2007-09-10 Composes de l'acide pyridylacetique

Country Status (17)

Country Link
US (1) US20090088419A1 (fr)
EP (1) EP1851202A1 (fr)
KR (1) KR20070106794A (fr)
CN (1) CN101166725A (fr)
AR (1) AR055563A1 (fr)
AU (1) AU2006217677A1 (fr)
BR (1) BRPI0607433A2 (fr)
CA (1) CA2598934A1 (fr)
CR (1) CR9369A (fr)
IL (1) IL185399A0 (fr)
MA (1) MA29323B1 (fr)
NO (1) NO20074668L (fr)
PE (1) PE20061099A1 (fr)
RU (1) RU2007135339A (fr)
TW (1) TW200640862A (fr)
WO (1) WO2006090915A1 (fr)
ZA (1) ZA200708144B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI354668B (en) 2006-06-27 2011-12-21 Takeda Pharmaceutical Fused cyclic compounds
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2308847B1 (fr) 2009-10-09 2014-04-02 EMC microcollections GmbH Pyridines substituées servant d'inhibiteurs de dipeptidyl-peptidase IV et leurs application pour le traitement du diabète et des maladies associées
US8648073B2 (en) 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
CN109305957B (zh) * 2017-07-26 2021-08-03 上海医药工业研究院 苯基吡啶类化合物及其在dpp-4酶抑制剂的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331010D1 (de) * 1992-07-03 2001-11-29 Smithkline Beecham Plc Benzoxazol- und benzothiazol-derivate als arzneimittel
US5827865A (en) * 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
EP1218336A2 (fr) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
ATE472536T1 (de) * 2002-02-13 2010-07-15 Hoffmann La Roche Pyridin- und pyrimidin-derivate
WO2004014860A2 (fr) * 2002-08-08 2004-02-19 Takeda Pharmaceutical Company Limited Composes heterocycliques fusionnes
AR045414A1 (es) * 2003-02-13 2005-10-26 Banyu Pharma Co Ltd Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
PE20050444A1 (es) * 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
AU2004291259A1 (en) * 2003-11-05 2005-06-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as PPAR activators
AU2004291262C1 (en) * 2003-11-05 2011-08-11 F. Hoffmann-La Roche Ag Phenyl derivatives as PPAR agonists

Also Published As

Publication number Publication date
RU2007135339A (ru) 2009-03-27
AR055563A1 (es) 2007-08-22
NO20074668L (no) 2007-11-15
BRPI0607433A2 (pt) 2009-09-08
WO2006090915A1 (fr) 2006-08-31
CN101166725A (zh) 2008-04-23
AU2006217677A1 (en) 2006-08-31
ZA200708144B (en) 2008-11-26
KR20070106794A (ko) 2007-11-05
US20090088419A1 (en) 2009-04-02
CA2598934A1 (fr) 2006-08-31
IL185399A0 (en) 2008-02-09
TW200640862A (en) 2006-12-01
PE20061099A1 (es) 2006-12-05
CR9369A (es) 2007-10-22
EP1851202A1 (fr) 2007-11-07

Similar Documents

Publication Publication Date Title
MA29323B1 (fr) Composes de l'acide pyridylacetique
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
MA30890B1 (fr) Compose indole
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
MY142807A (en) Benzimidazole derivative and use thereof.
MY134666A (en) Pyridinoylpiperidines as 5-ht1f agonists
MA29773B1 (fr) Derives de 1-h-pyrrole substitues par un groupe 1-heterocyclysulfonyle, 2-aminomethyle, 5-(hetero) aryle en tant qu'inhibiteurs des secretions acides
MA33851B1 (fr) Compose heterocyclique contenant de l'azote et fongicide agricole
MA32456B1 (fr) Dérivé hétérocyclique contenant du soufre ayant une activité inhibant la b-sécrétase
MA27626A1 (fr) Nouveaux derives de 2-pyridinecarboxamide
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA32642B1 (fr) Amides utiles en therapie
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
EA200700756A1 (ru) Пиримидоны
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
PE20050072A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
EA200400387A1 (ru) Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний
MA33072B1 (fr) Composes pyridazinone
NO20075723L (no) Tiazolforbindelser og fremgangsmater for anvendelse
WO2005092858A3 (fr) Composes alpha-aryle ou heteroaryle methyle beta piperidino propanamide en tant qu'antagoniste du recepteur orl1
WO2005012269A8 (fr) Nouveau compose azole
TW200621760A (en) 2-morpholino-4-pyrimidone compound
MA30813B1 (fr) Derives de 2-pyridinecarboxamide ayant un effet d'activation sur la gk.
TNSN07400A1 (fr) Derives d'aminoacides
EA200600570A1 (ru) Замещенные 2-карбониламино-6-пиперидинаминопиридины и замещенные 1-карбониламино-3-пиперидинаминобензолы как агонисты 5-ht